

192 - References

References

Schizophrenia and related psychoses CHAPTER 1 References

1. Suzuki Y, et al. Differences in plasma prolactin levels in patients with schizophrenia treated on monotherapy with five second-generation antipsychotics. *Schizophr Res* 2013; 145:116-119.
2. Tsuboi T, et al. Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. *Prog Neuropsychopharmacol Biol Psychiatry* 2013; 45:178-182.
3. Young RM, et al. Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele. *Br J Psychiatry* 2004; 185:147-151.
4. Haddad PM, et al. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. *Drugs* 2004; 64:2291-2314.
5. Holt RI, et al. Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management. *Clin Endocrinol (Oxf)* 2011; 74:141-147.
6. Leucht S, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. *Lancet* 2013; 382:951-962.
7. Peuskens J, et al. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. *CNS Drugs* 2014; 28:421-453.
8. Citrome L. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. *Expert Opin Drug Metab Toxicol* 2013; 9:193-206.
9. Marder SR, et al. Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies. *Acta Neuropsychiatr* 2017; 29:278-290.
10. Vanover KE, et al. Dopamine D(2) receptor occupancy of lumateperone (ITI-007): a positron emission tomography study in patients with schizophrenia. *Neuropsychopharmacology* 2019; 44:598-605.
11. Yunusa I, et al. Pimavanserin: a novel antipsychotic with potentials to address an unmet need of older adults with dementia-related psychosis. *Front Pharmacol* 2020; 11:87.
12. Correll CU, et al. Safety and tolerability of KarXT (xanomeline-trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia. *Schizophrenia (Heidelb)* 2022; 8:109.
13. Kaneda Y. The impact of prolactin elevation with antipsychotic medications on subjective quality of life in patients with schizophrenia. *Clin Neuropharmacol* 2003; 26:182-184.
14. Smith S, et al. The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. *J Clin Psychopharmacol* 2002; 22:109-114.

15. De Hert M, et al. Second-generation and newly approved antipsychotics, serum prolactin levels and sexual dysfunctions: a critical literature review. *Expert Opin Drug Saf* 2014; 13:605–624.
16. Baldwin D, et al. Sexual side-effects of antidepressant and antipsychotic drugs. *Adv Psychiatr Treat* 2003; 9:202–210.
17. Wieck A, et al. Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review. *Br J Psychiatry* 2003; 182:199–204.
18. Ali JA, et al. Delusions of pregnancy associated with increased prolactin concentrations produced by antipsychotic treatment. *Int J Neuropsychopharmacol* 2003; 6:111–115.
19. De Hert M, et al. Relationship between antipsychotic medication, serum prolactin levels and osteoporosis/osteoporotic fractures in patients with schizophrenia: a critical literature review. *Expert Opin Drug Saf* 2016; 15:809–823.
20. Tseng PT, et al. Bone mineral density in schizophrenia: an update of current meta-analysis and literature review under guideline of PRISMA. *Medicine (Baltimore)* 2015; 94:e1967.
21. De Hert M, et al. Relationship between prolactin, breast cancer risk, and antipsychotics in patients with schizophrenia: a critical review. *Acta Psychiatr Scand* 2016; 133:5–22.
22. Holt RI. Medical causes and consequences of hyperprolactinaemia: a context for psychiatrists. *J Psychopharmacol* 2008; 22:28–37.
23. Melmed S, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 2011; 96:273–288.
24. Montejo AL, et al. Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics. *Front Neuroendocrinol* 2017; 45:25–34.
25. Sá Esteves P, et al. Low doses of adjunctive aripiprazole as treatment for antipsychotic--induced hyperprolactinemia: a literature review. *Eur Psychiatry* 2015; 30 Suppl 1:393.
26. Yasui-Furukori N, et al. Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia. *J Clin Psychopharmacol* 2010; 30:596–599.
27. Meaney AM, et al. Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables. *Schizophr Res* 2007; 93:136–143.
28. Hamner MB, et al. Hyperprolactinaemia in antipsychotic-treated patients: guidelines for avoidance and management. *CNS Drugs* 1998; 10:209–222.
29. Duncan D, et al. Treatment of psychotropic-induced hyperprolactinaemia. *Psychiatr Bull* 1995; 19:755–757.
30. Cavallaro R, et al. Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. *J Clin Psychiatry* 2004; 65:187–190.
31. Zhuo C, et al. Safety and efficacy of high-dose vitamin B6 as an adjunctive treatment for antipsychotic-induced hyperprolactinemia in male patients with treatment-resistant schizophrenia. *Front Psychiatry* 2021; 12:681418.
32. Yuan HN, et al. A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia. *J Clin Psychopharmacol* 2008; 28:264–370.

schizophrenia: a randomized controlled trial. *J Clin Psychopharmacol* 2016; 36:572–579. 34. Krysiak R, et al. The effect of metformin on prolactin levels in patients with drug-induced hyperprolactinemia. *Eur J Intern Med* 2016; 30:94–98. 35. Lu Z, et al. Pharmacological treatment strategies for antipsychotic-induced hyperprolactinemia: a systematic review and network meta-analysis. *Transl Psychiatry* 2022; 12:267. 36. Zhang L, et al. Efficacy and safety of adjunctive aripiprazole, metformin, and paeoniae-glycyrrhiza decoction for antipsychotic-induced hyperprolactinemia: a network meta-analysis of randomized controlled trials. *Front Psychiatry* 2021; 12:728204. 37. Jiang Q, et al. Treatment of antipsychotic-induced hyperprolactinemia: an umbrella review of systematic reviews and meta-analyses. *Front Psychiatry* 2024; 15:1337274. 38. Walters J, et al. Clinical questions and uncertainty: prolactin measurement in patients with schizophrenia and bipolar disorder. *J Psychopharmacol* 2008; 22:82–89. 39. Chen CK, et al. Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics. *Prog Neuropsychopharmacol Biol Psychiatry* 2010; 34:1495–1499.

Revision #1

Created 2026-01-04 20:13:06 UTC by Omar Ayman

Updated 2026-01-04 20:13:06 UTC by Omar Ayman